Internal Medicine, Gastroenterology · Fayetteville, GA
NPI
1639173297
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1265 Highway 54 W, Ste 409
Fayetteville, GA, 30214
Phone (678) 817-6550
Groups this clinician bills Medicare through
Medicare paid, 2024
$440K
10,325 services
Medicare patients, 2024
1,131
Average age 74
Drug cost, 2024
$345K
2,853 prescriptions
Company payments, 2025
$556
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David M Gryboski was code 88305 (surgical pathology examination), 1,831 times for 660 patients. In total David M Gryboski billed 10,325 services in 53 codes, and Medicare paid $440K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-12-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 1,831 | 660 | $25.76 | $47K |
| 45384 Colonoscopy - Lesion Removal | Facility | 498 | 491 | $136.00 | $68K |
| 43239 Upper GI Endoscopy | Facility | 377 | 350 | $49.66 | $19K |
| 88313 Surgical Pathology Examination | Office | 375 | 251 | $56.03 | $21K |
| 99213 Office E&M - Established | Office | 288 | 209 | $66.96 | $19K |
| 88312 Surgical Pathology Examination | Office | 232 | 200 | $68.10 | $16K |
| 45385 Colonoscopy - Lesion Removal | Facility | 194 | 191 | $209.23 | $41K |
| 99214 Office E&M - Established | Office | 178 | 144 | $92.89 | $17K |
| 43248 Upper GI Endoscopy | Facility | 178 | 170 | $121.84 | $22K |
| 45380 Lower GI Endoscopy - Other | Facility | 100 | 99 | $69.55 | $6,955 |
| 99232 Hospital E&M - Subsequent | Facility | 66 | 37 | $62.71 | $4,139 |
| 99204 Office E&M - New | Office | 60 | 60 | $122.92 | $7,375 |
| 99203 Office E&M - New | Office | 50 | 50 | $76.45 | $3,823 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 48 | 48 | $182.61 | $8,765 |
| 99212 Office E&M - Established | Office | 37 | 29 | $41.24 | $1,526 |
By year: 2022 $366K for 7,949 services; 2023 $432K for 9,913 services; 2024 $440K for 10,325 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 1,831 | 660 | $25.76 | $47K |
| 88313 Surgical Pathology Examination | 375 | 251 | $56.03 | $21K |
| 88312 Surgical Pathology Examination | 232 | 200 | $68.10 | $16K |
Medicare prescription drug claims, 2024
In 2024, the drug David M Gryboski prescribed most often to Medicare patients was Pantoprazole Sodium, with 823 prescriptions and refills. In total David M Gryboski wrote 2,853 Medicare prescriptions that cost $345K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 823 | 1,721 | 294 | $6,683 |
| Sucralfate Generic | 401 | 617 | 182 | $21K |
| Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 255 | 255 | 249 | $36K |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 245 | 245 | 241 | $4,567 |
| Omeprazole Generic | 216 | 510 | 81 | $2,102 |
| Famotidine Generic | 90 | 183 | 34 | $714 |
| Ondansetron Odt Ondansetron | 59 | 59 | 59 | $418 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 57 | 67 | 21 | $1,508 |
| Cholestyramine Cholestyramine (With Sugar) | 55 | 62 | 32 | $3,913 |
| Mesalamine Generic | 50 | 87 | 13 | $21K |
| Dicyclomine Hcl Generic | 50 | 63 | 24 | $914 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 34 | 34 | 34 | $2,228 |
| Prednisone Generic | 31 | 39 | 14 | $117 |
| Linzess Linaclotide | 29 | 39 | Under 11 | $21K |
| Metoclopramide Hcl Generic | 28 | 35 | 12 | $268 |
Brand drugs: - claims; generic drugs: 2,389 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David M Gryboski $556 ($556 in general payments such as food, travel and fees) from 12 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $95.79.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $95.79 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 4 | $79.59 |
| Abbvie Inc. ABBV | 4 | $70.53 |
| Janssen Biotech, Inc. JNJ | 3 | $54.61 |
| Genzyme Corporation SNY | 2 | $50.44 |
| Madrigal Pharmaceuticals MDGL | 2 | $49.91 |
| Pfizer Inc. PFE | 2 | $38.46 |
| Organon LLC OGN | 2 | $37.16 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $28.74 |
| Ardelyx, Inc. ARDX | 1 | $22.21 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.